BioSpace News Archive

Newport Institute residential and outpatient primary mental health treatment programs address escalating young adult issues

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of their latest market trend analysis for a company in the pharma packaging industry.

Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, provides an update on the interim futility analysis of the PHOCUS study of Pexa-Vec in liver cancer.

GlobalMed Technologies (GMT), a leader in international medical device manufacturing and sales, announced today that, DermaConcepts, its U.S. distribution partner for GlycoAla®, will be holding educational events for medical and aesthetic providers in August and September.

Revenues of $4.3 billion

Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic), a biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that it will report its financial results for the second quarter ended June 30th, 2019

Friedberg will lead the company’s performance measurement and improvement efforts

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today the successful enrollment and operation of the first two patients in the Agili-C™ Investigational Device Exemption (IDE) pivotal study at Hospital for Special Surgery (HSS), New York, NY.

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, “Aevi”) today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human monoclonal antibody (mAb) that targets interleukin 18 (IL-18).

Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, announced the appointment of Brian Kotzin, M.D., to its board of directors